DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES

• US 20110212449A1
• Filed: 04/05/2011
• Published: 09/01/2011
• Est. Priority Date: 09/29/1999
• Status: Active Grant

• Current Assignee: Gen-Probe Incorporated (Hologic Incorporated)
• Original Assignee: Diagnocure Inc.
• Inventors: BUSSE, Ursula, CHYPRE, Camille, FRADET, Yves
• Granted Patent: US 8,241,848 B2
• Time in Patent Office: Days
• US Class Current: 435/6.11
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 16/3069 Reproductive system, e.g. ovaria, uterus, testes, prostate
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2333/47 Assays involving proteins of known structure or function as defined in the subgroups
• CPC Class Codes: G01N 2800/56 Staging of a disease; Further complications associated with the disease
• CPC Class Codes: G01N 33/57434 of prostate

Abstract

This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.

Claims

1. A method of determining the malignancy status of prostate cells contained in a sample undergoing testing, said method comprising determining from PCA3 RNAs from prostate cells contained in said sample or from cDNAs derived therefrom, whether said PCA3 RNAs or cDNAs comprise or lack an additional sequence between PCA3 exon 3 and PCA3 exon 4a, said additional sequence consisting essentially of nucleotides 27 to 254 of SEQ ID NO:

1,

wherein a presence or level of a PCA3 nucleic acid molecule comprising said additional sequence is indicative of a non-malignant status of said prostate cells, and

wherein a presence or level of a PCA3 nucleic acid molecule which lacks said additional sequence and comprises nucleotide positions 26 and 27 of SEQ ID NO;

2, which define the PCA3 exon 3-exon 4a junction, is indicative of a malignant status of said prostate cells.

2. The method of claim 1, comprising the use of a first oligonucleotide which binds to:

a) PCA3 exon 3;

b) PCA3 exon 4a;

c) the PCA3 exon 3-exon 4a junction;

d) the PCA3 exon 3-intron 3 junction;

or

e) the PCA3 intron 3-exon 4a junction.

3. The method of claim 2, wherein said oligonucleotide is at least 10 nucleotides in length.

4. The method of claim 2, wherein said oligonucleotide is at least 12 nucleotides in length.

5. The method of claim 2, wherein said oligonucleotide is at least 15 nucleotides in length.

6. The method of claim 2, wherein said oligonucleotide is at least 20 nucleotides in length.

7. The method of claim 2, wherein said oligonucleotide is at least 18 to about 50 nucleotides in length.

8. The method of claim 2, wherein said oligonucleotide is at least 20 to about 35 nucleotides in length.

9. The method of claim 2, wherein said oligonucleotide is detectably labeled.

10. The method of claim 9, wherein said oligonucleotide hybridizes under high stringency conditions to at least 10 consecutive nucleotides of a sequence comprising nucleotides 26 and 27 of SEQ ID NO:

2.

11. The method of claim 10, wherein said oligonucleotide hybridizes under high stringency conditions to at least 15 consecutive nucleotides of a sequence comprising nucleotides 26 and 27 of SEQ ID NO:

2.

12. The method of claim 10, wherein said oligonucleotide hybridizes under high stringency conditionsto at least 20 consecutive nucleotides of a sequence comprising nucleotides 26 and 27 of SEQ ID NO:

2.

13. The method of claim 10, wherein said high stringency conditions comprise a hybridization at 65°

C. in 5×

SSC, 5×

Denhardt'"'"'s solution, 1% SDS, and 100 μ

g/ml denatured salmon sperm DNA.

14. The method of claim 2, further comprising an amplification reaction.

15. The method of claim 14, wherein said amplification reaction comprises a reaction selected from the group consisting of a nucleic acid sequence-based amplification reaction (NASBA), a polymerase chain reaction (PCR), a transcription-based amplification reaction, a strand displacement amplification (SDA), a ligase chain reaction (LCR), and a Qβ

replicase reaction.

16. The method of claim 15, wherein said first oligonucleotide binds to a sequence comprised in nucleotides 1 to 26 of SEQ ID NO:

1, or to a sequence comprised in nucleotides 255 to 506 of SEQ ID NO;

1.

17. A kit for determining whether PCA3 RNA contained in a patient sample, comprises or lacks an additional sequence between PCA3 exon 3 and PCA3 exon 4a, said additional sequence consisting essentially of nucleotides 27 to 254 of SEQ ID NO:

1, said kit comprising at least two oligonucleotides which bind to a PCA3 nucleic acid comprising a sequence selected from the group consisting of;

i) the PCA3 exon 3-exon 4a junction defined by nucleotide positions 26 and 255 of SEQ ID NO;

1, and by nucleotide positions 26 and 27 of SEQ ID NO;

2;

ii) the PCA3 exon 3-intron 3 junction defined by nucleotide positions 26 and 27 of SEQ ID NO;

1; and

iii) the PCA3 intron 3-exon 4a junction defined by nucleotide positions 254 and 255 of SEQ ID NO;

1,

wherein a presence or level of a PCA3 nucleic acid molecule comprising said additional sequence is indicative of a non-malignant status of said prostate cells, and

wherein a presence or level of a PCA3 nucleic acid molecule which lacks said additional sequence and comprises nucleotide positions 26 and 27 of SEQ ID NO;

2, which define the PCA3 exon 3-exon 4a junction, is indicative of a malignant status of said prostate cells.

18. A method of distinguishing differentially expressed PCA3 nucleic acids that indicate the malignancy status of prostate cells contained in a sample undergoing testing, said method comprising:

(a) performing a nucleic acid amplification reaction using RNAs obtained from prostate cells contained in said sample as templates with a pair of oligonucleotides that amplify PCA3 nucleic acid sequences across nucleotide positions 26 and 255 of SEQ ID NO;

1, which respectively define the PCA3 exon 3-intron 3 and intron 3-exon 4a junctions, and nucleotide positions 26 and 27 of SEQ ID NO;

2, which define the PCA3 exon 3-exon 4a junction, yielding first and second amplification products, wherein said pair of oligonucleotides comprises;

(i) a first oligonucleotide which binds to, or upstream of, nucleotide position 26 of SEQ ID NO;

1, and

(ii) a second oligonucleotide which binds to, or downstream of, nucleotide position 255 of SEQ ID NO;

1,

wherein said first amplification product results from an amplification of a first PCA3 RNA that comprises portions of exon 3 and exon 4a sequences and an additional sequence between PCA3 exon 3 and PCA3 exon 4a, said additional sequence consisting essentially of nucleotides 27 to 254 of SEQ ID NO;

1, and

wherein said second amplification product results from an amplification of a second PCA3 RNA that comprises portions of exon 3 and exon 4a sequences with PCA3 exon 3 joined to PCA3 exon 4a without including said additional sequence; and

(b) detecting one of said first and second amplification products independent of the other, thereby distinguishing differentially expressed PCA3 nucleic acids that indicate the malignancy status of prostate cells contained in said sample.